Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • dustar1986
    Junior Member
    • Sep 2011
    • 8

    Highly Inflated DE Result using Several Linear Models

    Dear Colleagues,

    I'm working on a disease treatment study. I got RNA-seq samples of cell-line from 7 patients and 7 normal persons (both consist of 3 males and 4 females). Each individual was given with 3 different treatments including a vehicle control. So that I got 42 RNA libraries in all.

    I tried several linear models. In DESeq2 and Limma I used a design to compare between and within groups, which looks like:
    Expression ~ Genotype + Genotype:Individual.nested + Genotype:Treatment

    As I got 42 samples, I think I'm kind of having enough observations to estimate variance in a normal way, instead of using the assumption that genes with similar expression levels would have similar dispersions. So I also tried a mixed model using lme4 package, and using batches and indivduals as random effects. It was built by LMM instead of GLMM:
    Expression ~ Genotype*Gender*Treatment + (1|Batch) + (1|Individual)

    When I calculated contrasts (i.e. Treatment A effect on Normal), all these models gave highly inflated raw p values (more than 8000 significant genes). Limma and DESeq2 results had a >95% overlap and they had a > 65% overlap with lme4. This doesn't make sense for me not just because of the p value distribution. Treatment A is a proved treatment on patient. This contrast, which test for its off-target on normal people, turned out a shocked result.

    I'm pretty sure the contrast was done in a correct way, involving the correct beta's. Any suggestion is really appreciated. Thanks a lot.

Latest Articles

Collapse

  • mylaser
    Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by mylaser
    Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
    If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
    This guide explains everything you need to know about...
    Yesterday, 01:13 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-08-2026, 10:08 AM
0 responses
12 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-07-2026, 11:05 AM
0 responses
30 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-02-2026, 11:08 AM
0 responses
31 views
0 reactions
Last Post SEQadmin2  
Working...